u regulator rule pain drug u food drug regulator decide friday whether recommend sale painkiller linked high risk heart attack stroke food drug administration fda advisory panel give verdict hearing evidence three day painkiller called cox inhibitor sold brand name celebrex vioxx vioxx withdrawn shop last year merck said would consider selling get fda approval fda asked decide benefit patient justify increased risk putting vioxx back shelf likely boost profit merck make easier legal battle people claim injured drug analyst said merck voluntarily stopped sale vioxx 30 september move caused firm's fourth quarter earnings slide 1bn 581m 4bn year earlier merck's share tumbled 10 news company set aside million dollar cover cost vioxx related litigation alarm bell rung research note called approve showed risk heart attack stroke doubled patient taking drug least 18 month cox inhibitor developed drug company including merck pfizer cause user fewer stomach problem painkiller pfizer still selling celebrex bextra product though investigation suggested may also harmful heart merck's announcement possible reintroduction vioxx caught analyst surprise merck's head research peter kim said withdrew vioxx based information available u time knowing alternative therapy went say thing since changed light new report given new information clear cardiovascular risk observed approve make vioxx unique class similar drug marketed u mr kim explained thursday david graham fda's office drug safety told advisory panel really appear need cox inhibitor according calculation presented u senate dr graham november vioxx may linked many 56 000 american death facing stem criticism handling vioxx case fda said tuesday create independent body oversee safety drug already market place european regulator meanwhile ruled thursday patient heart disease stroke take cox inhibitor european medicine agency also said doctor cautious giving drug patient risk factor heart disease